GlassScriptPhysician profile
Philip J Finocchiaro
NPI 1538143730
$998.50
in general payments reported to CMS, 2019-2025
15 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $173 · 2023: $159 · 2024: $381 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $341.60 | 2022-2025 | |
| Pfizer INC. | $217.06 | 2022-2025 | |
| Novo Nordisk INC | $177.53 | 2023-2025 | Wegovy, Rybelsus, Saxenda |
| Ardelyx, INC. | $33.04 | 2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $27.66 | 2022 | |
| Becton, Dickinson and Company | $23.85 | 2025 | Bd Onclarity |
| Boston Scientific Corporation | $22.34 | 2025 | Bodyguardian |
| Exact Sciences Corporation | $21.53 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $20.99 | 2025 | Zepbound, Mounjaro |
| Shield Therapeutics INC | $20.14 | 2024 | |
| Lucid Diagnostics INC. | $19.73 | 2024 | |
| Heartflow, INC. | $19.53 | 2022 | |
| Merck Sharp & Dohme LLC | $19.06 | 2025 | Capvaxive, Gardasil 9, M-M-R II |
| Acerus Pharmaceuticals Corporation | $18.21 | 2022 | |
| Echosens North America, INC. | $16.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Finocchiaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.